In this episode of Patient Innovations, we dive into Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease—a progressive neurodegenerative condition that affects nerve cells in the brain and spinal cord.

Joining us in the studio are:

• Mark Bearman – An ALS patient with a genetic mutation, sharing his personal journey.
• Dr. Sam Maiser – Chair of the Department of Neurology at Hennepin Healthcare, offering medical insights.
• Jennifer Hjelle – Chief Community Engagement Officer for the ALS Association, discussing advocacy and resources.

ALS, which currently has no known cure, often begins with muscle weakness in the hands, feet, arms, or legs before progressing to other parts of the body. As nerve cells die, movement becomes more difficult, eventually impacting chewing, swallowing, speaking, and breathing.

The Ice Bucket Challenge became a historic movement, raising millions of dollars for ALS research. These efforts contributed to the development of the first drug showing significant potential in treating genetically induced ALS.

 Learn more, find resources, and support advocacy efforts at The ALS Association – dedicated to finding a cure for ALS.